Salivary Inflammatory Biomarkers: Predictors & Comparative Effects of Sonicare/Elite-Flexcare in Stages of Perio Disease
NCT ID: NCT02187185
Last Updated: 2018-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
175 participants
INTERVENTIONAL
2009-04-30
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of a Sonic Toothbrush on the Abrasion of the Gingival Tissue
NCT05375227
At-Home Care for Subjects With Periodontitis
NCT04254770
A Clinical Study to Evaluate the Effectiveness of an Experimental Toothpaste in Improving Gum Health and Reducing Plaque Accumulation
NCT07255040
Plaque and Gingivitis Evaluation of a U-Shaped Toothbrush in a 30-Day Model
NCT06122376
A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice Containing Stannous Fluoride
NCT04123665
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This research study has both a Diagnostic Aim and a Treatment Aim. Aim #1 is to examine the utility of candidate inflammatory biomarkers within saliva to discriminate between health, gingivitis, mild, moderate and severe periodontis; and to discriminate between active versus inactive states of periodontal disease to see if these basal levels can predict the clinical response to biofilm overgrowth among various periodontal conditions; Aim #2 is to extend the claim of the anti-inflammatory and anti-infective efficacy of the Sonicare/Elite-Flexcare as compared to manual brushing to include 4 levels of periodontal disease \[BGI-G, P1, P2 and P3\].
The devices used in this study are subject only to Class I (general controls) and considered exempt from the premarket notification procedures and not subject to section 510(k), 515, or 520(m,) of the FDC Act in order to be legally marketed. Thus, the study does not meet the definition of an Applicable Clinical Trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sonicare Elite-Flexcare
Arm 1 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the Sonicare/Elite/Flexcare toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
Sonicare/Elite-Flexcare Toothbrush
Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
Manual Toothbrush
Arm 2 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the manual toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
Manual Toothbrush
traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sonicare/Elite-Flexcare Toothbrush
Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
Manual Toothbrush
traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. able and willing to follow study procedures and instructions.
3. read, understood and signed an informed consent form.
4. present with at least 8 teeth in the functional dentition with a minimum of 3 adjacent teeth with interproximal papilla in each posterior sextant that will have the stent.
5. be in good general health.
6. present with one of the following five categories to be considered for enrollment
* BGI health (all PD\<3mm, BOP\<10%)
* BGI-gingivitis (all PD≤3mm, BOP≥10%)
* BGI-P1 (1+ site with PD\>3mm, BOP≤10%)
* BGI-P2 (1+ site with PD\>3mm, BOP\>10% but BOP≤50%)
* BGI-P3 (1+ site with PD\>3mm, BOP\>50%)
Exclusion Criteria
2. gross oral pathology.
3. treatment with antibiotics for any medical or dental condition within 1 month prior to the screening examination.
4. chronic treatment (i.e., two weeks or more) with any medication known to affect periodontal status (e.g., phenytoin, calcium antagonists, cyclosporin, anticoagulants, non-steroidal anti-inflammatory drugs, high dose aspirin such as \>100mg per day) within one month of the screening examination.
5. ongoing medications initiated less than three months prior to enrollment (i.e., medications for chronic medical conditions must be initiated at least three months prior to enrollment).
6. clinically significant organ disease including impaired renal function, and/or any bleeding disorder.
7. severe unrestored caries, or any condition that is likely to require antibiotic treatment during the study, including the need for prophylactic antibiotic.
8. use any tobacco products or who have used tobacco products within the previous six months of the screening examination.
9. pregnant, or expect to become pregnant within the next three months and individuals nursing.
10. dental appliances that will interfere with stent construction.
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philips Oral Healthcare
INDUSTRY
University of North Carolina, Chapel Hill
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven Offenbacher, DDS PhD MMSc
Role: PRINCIPAL_INVESTIGATOR
The University of North Carolina at Chapel Hill School of Dentistry
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of North Carolina at Chapel Hill School of Dentistry
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-0627
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.